Radiation Oncology (Oct 2024)

Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis

  • Sebastian M. Christ,
  • Gabriel W. Thiel,
  • Philip Heesen,
  • Siyer Roohani,
  • Michael Mayinger,
  • Jonas Willmann,
  • Maiwand Ahmadsei,
  • Urs J. Muehlematter,
  • Alexander Maurer,
  • Josef A. Buchner,
  • Jan C. Peeken,
  • Rifaquat Rahman,
  • Ayal Aizer,
  • Emilie Le Rhun,
  • Nicolaus Andratschke,
  • Michael Weller,
  • Martin Huellner,
  • Matthias Guckenberger

DOI
https://doi.org/10.1186/s13014-024-02542-2
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background and introduction Increasing evidence suggests that a subgroup of patients with oligometastatic cancer might achieve a prolonged disease-free survival through local therapy for all active cancer lesions. Our aims are to investigate the impact of brain metastases on the classification, treatment, and outcome in these patients. Materials and methods We analyzed a total of 7,000 oncological positron emission tomography scans to identify patients with extracranial oligometastatic disease (defined as ≤ 5 intra- or extra-cranial metastases). Concurrent magnetic resonance imaging brain was assessed to quantify intracranial tumor burden. We investigated the impact of brain metastases on oligometastatic disease state, therapeutic approaches, and outcome. Predictors for transitioning from oligo- to polymetastatic states were evaluated using regression analysis. Results A total of 106 patients with extracranial oligometastases and simultaneous brain metastases were identified, primarily originating from skin or lung/pleura cancers (90%, n = 96). Brain metastases caused a transition from an extracranial oligometastatic to a whole-body polymetastatic state in 45% (n = 48) of patients. While oligometastatic patients received systemic therapy (55% vs. 35%) more frequently and radiotherapy for brain metastases was more often prescribed to polymetastatic patients (44% vs. 26%), the therapeutic approach did not differ systematically between both sub-groups. The oligometastatic sub-group had a median overall survival of 28 months compared to 10 months in the polymetastatic sub-group (p < 0.01). Conclusion In patients with brain metastases, a low total tumor burden with an oligometastatic disease state remained a significant prognostic factor for overall survival. Presence of brain metastases should therefore not serve as exclusion criterion for clinical trials in the field of oligometastatic disease. Moreover, it underscores the importance of considering a multimodality treatment strategy in oligometastatic cancer patients.

Keywords